뒤로
Minerva Neurosciences Inc (NERV) 수입
NERV 주가 차트
NERV 수입
Minerva Neurosciences Inc
$6.18
0.65%
$0.04
종가: Mar 27, 16:00:00 GMT-4
$6.18
0%
$0
애프터마켓: Mar 27, 20:00:00 GMT-4
최신 수익 결과: Q4 '25
보고됨: 2026-03-11
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
NERV의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Minerva Neurosciences Inc NERV의 지난 분기 매출 실적은 어땠나요?
Minerva Neurosciences Inc의 매출 추정치는 얼마인가요?
Minerva Neurosciences Inc의 수익 품질 점수는 얼마인가요?
Minerva Neurosciences Inc는 언제 수익을 보고하나요?
Minerva Neurosciences Inc의 예상 수익은 얼마인가요?
Minerva Neurosciences Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$6.14
시가
$5.96
일일 범위
$5.96 - $6.5
52주 범위
$1.15 - $12.46
거래량
167.7K
평균 거래량
184.3K
배당수익률
--
EPS(TTM)
-1.85
시가총액
$267.4M
NERV란 무엇인가요?
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.